Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 and Nivolumab in advanced biliary tract cancer
NCT04057365Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
A Phase 2 trial of sirexatamab in biliary tract cancer (BTC), sponsored by Massachusetts General Hospital. Started Oct 2019; status: terminated.
02
Drugs
sirexatamab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04057365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04057365.